These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10140430)

  • 1. Technical considerations in the preparation and dispensing of chemotherapy.
    Peters BG
    Top Hosp Pharm Manage; 1995 Jan; 14(4):78-88. PubMed ID: 10140430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-assurance testing of staff pharmacists handling cytotoxic agents.
    Harrison BR; Godefroid RJ; Kavanaugh EA
    Am J Health Syst Pharm; 1996 Feb; 53(4):402-7. PubMed ID: 8673660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of chemotherapy drug preparation process in hospitals in Turkey - A pilot study.
    Bayraktar-Ekincioglu A; Korubük G; Demirkan K
    J Oncol Pharm Pract; 2018 Dec; 24(8):563-573. PubMed ID: 28728495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence to Precautionary Guidelines for Compounding Antineoplastic Drugs: A Survey of Nurses and Pharmacy Practitioners.
    Boiano JM; Steege AL; Sweeney MH
    J Occup Environ Hyg; 2015; 12(9):588-602. PubMed ID: 25897702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of two work practice changes on the microbial contamination rates of pharmacy-compounded sterile preparations.
    Trissel LA; Gentempo JA; Saenz LM; Woodard MY; Angeles CH
    Am J Health Syst Pharm; 2007 Apr; 64(8):837-41. PubMed ID: 17420200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safe Handling of Cancer Chemotherapy Drugs in Pharmacy(Preparations, Transport and Safe Deposit)].
    Nomura H
    Gan To Kagaku Ryoho; 2017 Jul; 44(7):554-557. PubMed ID: 28790255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Validation of aseptic technique of parenteral nutrition compounding in a pharmacy service according to USP Chapter 797].
    Romero Jiménez RM; Pernía López MS; Sánchez Fresneda MN; Sanjurjo Sáez M
    Nutr Hosp; 2013; 28(5):1494-7. PubMed ID: 24160206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of the aseptic processing environment.
    Frieben WR
    Am J Hosp Pharm; 1983 Nov; 40(11):1928-35. PubMed ID: 6650522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks to health professionals from hazardous drugs in Japan: a pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide.
    Sugiura S; Asano M; Kinoshita K; Tanimura M; Nabeshima T
    J Oncol Pharm Pract; 2011 Mar; 17(1):14-9. PubMed ID: 20179165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Continuous training program for technicians handling antineoplastic drugs and occupational exposure risk].
    Dussart C; Favier B; Gilles L; Camal I; Almeras D; Latour JF; Grelaud G
    Bull Cancer; 2008 Sep; 95(9):821-2. PubMed ID: 18829414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASHP statement on bar-code verification during inventory, preparation, and dispensing of medications.
    American Society of Health-System Pharmacists
    Am J Health Syst Pharm; 2011 Mar; 68(5):442-5. PubMed ID: 21330687
    [No Abstract]   [Full Text] [Related]  

  • 12. Monitoring of aseptic preparation by closed-circuit television.
    Ryan S
    J Telemed Telecare; 1997; 3(3):174-6. PubMed ID: 9489115
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacy compounding of high-risk level products and patient safety.
    Mullarkey T
    Am J Health Syst Pharm; 2009 Sep; 66(17 Suppl 5):S4-13. PubMed ID: 19710449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation.
    Sessink PJ; Leclercq GM; Wouters DM; Halbardier L; Hammad C; Kassoul N
    J Oncol Pharm Pract; 2015 Apr; 21(2):118-27. PubMed ID: 24567041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiological validation of a robot for the sterile compounding of injectable non-hazardous medications in a hospital environment.
    Sabatini L; Paolucci D; Marinelli F; Pianetti A; Sbaffo M; Bufarini C; Sisti M
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e63-e68. PubMed ID: 32296508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a flowchart for risk assessment and allocation of preparation of monoclonal antibodies.
    Bauters T; Vandenbroucke J
    J Oncol Pharm Pract; 2019 Jan; 25(1):187-191. PubMed ID: 29199505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for handling cytotoxic drugs in hospitals.
    Stolar MH; Power LA; Viele CS
    Am J Hosp Pharm; 1983 Jul; 40(7):1163-71. PubMed ID: 6881154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aseptic technique in microgravity.
    McCuaig K
    Surg Gynecol Obstet; 1992 Nov; 175(5):466-76. PubMed ID: 1440179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Handling of gene-transfer products by the National Institutes of Health Clinical Center pharmacy department.
    DeCederfelt HJ; Grimes GJ; Green L; DeCederfelt RO; Daniels CE
    Am J Health Syst Pharm; 1997 Jul; 54(14):1604-10. PubMed ID: 9248603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aseptic simulation test for cytotoxic drug production in isolators.
    Savry A; Correard F; Bennis Y; Roubaud S; Gauthier-Villano L; Pisano P; Pourroy B
    Am J Health Syst Pharm; 2014 Mar; 71(6):476-81. PubMed ID: 24589539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.